ライブ

FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach CellDecoding the spatiotemporal development of human meninges CellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation CellPhysiological brain clearance architecture revealed by neuronal protein tracing FierceBiotechASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Endpoints NewsCan AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more IlluminaIllumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360 BioPharma DiveAt ASCO, Merck makes case for a ‘cornerstone’ cancer drug BioPharma DiveBristol Myers unveils data for one of its next-gen blood cancer drugs Clinical OMICsTeclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma Clinical OMICsAI Chatbots Do Not Consistently Deliver Accurate Health Responses FierceBiotechLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform

FierceBiotech 2026年5月29日

Chutes & Ladders—Allogene swaps in CMO as new chief exec

After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zach...

After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zachary Roberts, M.D., Ph.D., the biotech’s chief medical officer and head of R&D, can take his place starting June 30.